Price Targets Lifted as Johnson & Johnson Eyes $100.5B 2026 Revenue
Johnson & Johnson shares rose 53% over the past year and 15% year-to-date, driven by 6% revenue growth to $94.2B in 2025 and a $100.5B revenue target for 2026. Oric Pharmaceuticals targets a Phase 3 trial in 1H 2025 combining its PRC2 inhibitor rinzimetostat with Johnson & Johnson’s apalutamide.
1. Share Performance and Analyst Upgrades
Johnson & Johnson shares have rebounded strongly, gaining 53% over the past year and 15% year-to-date. RBC Capital raised its price target to $255 from $240 with an Outperform rating, while Bank of America lifted its target to $227 from $221, citing strength in the cancer drug portfolio and solid financial footing.
2. Financial Results and Guidance
The company delivered 6% revenue growth to $94.2 billion in 2025 and outlined a $100.5 billion revenue target for 2026, fueled by its oncology franchise and upcoming orthopedic spinoff. Management highlighted robust pharmaceutical cash flows as a key driver of the optimistic outlook.
3. Oric Collaboration Trial Plans
Oric Pharmaceuticals plans to initiate a Phase 3 study in the first half of 2025 combining its PRC2 inhibitor rinzimetostat with Johnson & Johnson’s apalutamide. Early safety and efficacy signals underpin the collaboration, which could expand apalutamide’s market presence in prostate cancer treatment.